| abstract |
Compounds of formula (I) wherein R1, R2, R3 and R4 are each H or C1-C4 alkyl; R5 is (CH2)m NHSO2R6 or (CH)m NHCOR6; R6 is C1-C6 alkyl, C3-C6 cycloalkyl optionally substituted by aryl, aryl or heteroaryl; R7 is H, C1-C4 alkyl, C1-C4 alkoxy, halo, CF3, OCF3, CN, CONH2, or S(O)n(C1-C4 alkyl); X is CH2, CHCH3, CH(OH), C(OH)CH3, C=CH2, CO or O; m is 0 or 1 and n is 0, 1 or 2, and their pharmaceutically acceptable salts and biolabile esters, are antagonists of thromboxane A2 of utility, particularly in combination with a thromboxane synthetase inhibitor, in the treatment of athero-sclerosis and unstable angina and for prevention of reocclusion after percutaneous transluminal angioplasty. |